HCL Technologies (HCL), a global technology company, has signed a multi-year contract with Genmab, an international biotechnology company, to support its IT infrastructure operations globally through a new future-proof digital foundation that spans hybrid cloud, cybersecurity, unified service management and digital workplace services.
Copenhagen, Denmark-based Genmab is the creator of multiple antibody therapeutics, and its core purpose is to improve the lives of people with cancer. The company has locations in Utrecht, the Netherlands; Princeton, New Jersey, US and Tokyo.
To support the company’s rapid growth, HCL’s centralised global service delivery model and innovative frameworks will enable Genmab to realise greater automation, improved cost transparency, enhanced operational efficiency and increased control.
